New treatments for dry eye may improve care

Article

Ongoing development of dry eye treatments in the pipeline aims to address the range of etiologies and pathophysiologies present across patients with dry eye syndrome.

Ongoing development of dry eye treatments in the pipeline aims to address the range of etiologies and pathophysiologies present across patients with dry eye syndrome. Researchers are hoping to boost patient compliance with existing and future therapies by reducing dosing frequencies and combining products where possible.

Following is a brief update on the latest drug developments.

Farthest along the pipeline

Coming attractions

Anti-inflammatory

Exciting new drugs and delivery methods are in the research pipeline, which target inflammation in the anterior and posterior segments and address unmet needs in diseases such as uveitis and endophthalmitis.

Phase II and III development

Preclinical pipeline

Anti-infectives and combinations

The rapid evolution of pathogenic bacteria and increasing resistance necessitates the continual development of antibiotics. The most recent addition to the ocular antibiotic market, besifloxacin ophthalmic suspension 0.6% (Besivance, Bausch & Lomb), has no previous systemic use and has shown antimicrobial activity against fluoroquinolone-resistant staphylococci and multi-drug resistant strains.18

Companies are also pursuing formulations that will simplify treatment regimens by lowering dosing frequency as well as new fixed combination products that contain both an antibiotic and an anti-inflammatory for the treatment of inflammation when there is a risk of bacterial infection.

Phase II and III development

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.